Short Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Decreases By 22.0%

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a significant drop in short interest in October. As of October 31st, there was short interest totalling 52,600 shares, a drop of 22.0% from the October 15th total of 67,400 shares. Based on an average daily volume of 47,600 shares, the short-interest ratio is currently 1.1 days.

Hedge Funds Weigh In On Evaxion Biotech A/S

An institutional investor recently bought a new stake in Evaxion Biotech A/S stock. Invst LLC acquired a new position in Evaxion Biotech A/S (NASDAQ:EVAX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned about 1.00% of Evaxion Biotech A/S as of its most recent filing with the Securities and Exchange Commission. 11.04% of the stock is owned by institutional investors.

Evaxion Biotech A/S Price Performance

NASDAQ:EVAX traded down $0.24 during mid-day trading on Friday, hitting $1.44. 76,290 shares of the stock traded hands, compared to its average volume of 28,397. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. Evaxion Biotech A/S has a 12-month low of $1.40 and a 12-month high of $13.61. The business’s 50-day moving average price is $2.77 and its 200 day moving average price is $3.06.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The company had revenue of $3.02 million during the quarter, compared to analysts’ expectations of $0.19 million. Research analysts predict that Evaxion Biotech A/S will post -0.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a research note on Friday, November 1st.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.